2020 | 2021 | ||||||
Price: | 95.50 | EPS | 5.80 | 12.70 | |||
Shares Out. (in M): | 68 | P/E | 16.5 | 7.5 | |||
Market Cap (in $M): | 6,513 | P/FCF | NA | NA | |||
Net Debt (in $M): | -740 | EBIT | 384 | 881 | |||
TEV (in $M): | 5,773 | TEV/EBIT | 15 | 6.5 |
Sign up for free guest access to view investment idea with a 45 days delay.
What is the mortality effect of COVID-19 on RGA's Traditional Life Insurance Business?
Exhibit 1: Number of COVID-19 Cases in U.S
Exhibit 2: Number of COVID-19 Cases in U.S
What is the impact from lower interest rates on profitability and what are the credit risks in RGA’s investment portfolio?
RGA derives a majority of its income (~50%) from life reinsurance, which is sensitive to mortality but not as sensitive to rates. In particular, RGA is much less exposed to (i) annuities and (ii) pension products, which rely on earning a spread between liabilities and interest-earnings-assets. The annuity/pension exposure that RGA does have is lower interest rate risk because RGA is reinsuring seasoned blocks of business that are re-priced upon the transaction. Importantly, RGA’s business is 100% reinsurance where it is easier to match the duration of assets and liabilities when compared to writing new primary business. As a result, RGA’s earnings are much less affected by declines of interest rates relative to its peers. With that said, low interest rates still present some earnings headwind for the company, given the long-term nature of RGA’s businesses. The CFO cited a $(30)m-(35)m annual pre-tax impact on earnings or $0.33 - $0.39 of EPS, for every (50) basis point decline in earned rates. Currently new money rate was 3.57% in Q2 2020 vs. current investment yield of 4.07%.
With regard to the investment portfolio, approximately 95% of RGA’s investment portfolio was rated investment grade at 2Q20, with an average credit rating of A. RGA’s CLO portfolio ($1.8bn – 2.5% of investment portfolio) has an average credit rating of AA. The commercial mortgage loan portfolio ($6.0bn – 8.3% of investment portfolio) has an average loan-to-value of 58%. The average commercial loan size is $10.2 million, which equates to a diversified portfolio of over ~575 individual loans. The company implemented interest only or payment deferral modifications on approximately 10% of its CML portfolio, as of 2Q20, and expects to collect all deferred interest. There were no loan impairments in the 2Q20, although CECL reserve increased due to macro-economic factors. The company reported -$22m of credit impairments in 2Q20. For context, this is 0.03% of the total investment portfolio of $72 billion.
Management
The CEO has been with the company since 2014 and CFO since 1995. We give management credit for growing book value per share at a +11% CAGR since 2008. Hindsight may prove that the capital raise in June at a steep discount to book value was a poor decision; however, to be fair there was substantially greater COVID-19 uncertainty at the time.
Valuation
RGA currently trades at 0.49x book value, 0.72x book value (excl. AOCI) and 7.5x 2021 EPS. RGA has a long-term track record of generating an 11% ROEs since the great financial crisis and double-digit book value growth. To date, COVID-19 has been an earnings event, not a capital event for the company, and it increasingly looks like that will continue to be the case. As such, our fair value target is $135 (~45% upside) based on 0.70x estimated 2021 book value. Over the next few years we believe the shares can effectively double to $180 if the stock simply trades back to a 0.80x BV multiple. For the past 15 years, the stock has generally traded between 0.8x-1.2x book value, so anything above a 0.8x would offer further upside potential.
Modeling Assumptions
2020 |
2021 |
2022 |
2023 |
|
Net Premiums |
$11,506 |
$12,190 |
$13,006 |
$13,874 |
Investment Income |
2,551 |
2,679 |
2,772 |
2,876 |
Total Revenue |
14,414 |
15,248 |
16,174 |
17,163 |
Operating Expenses |
13,915 |
14,096 |
14,965 |
15,898 |
NOI |
384 |
881 |
925 |
968 |
EPS |
5.80 |
12.70 |
13.70 |
15.00 |
BVPS |
186 |
196 |
211 |
227 |
Target Multiple |
0.7x |
0.7x |
0.8x |
0.8x |
Fair Value |
130 |
137 |
169 |
182 |
% Up/(Downside) |
36% |
43% |
77% |
91% |
Risks
COVID-19 mutation increasing mortality; larger waves of infections during the Northern Hemisphere winter
Continued declines in rates further pressuring investment yield
There is an opportunity to have positive new flows on therapeutics and the vaccine in the coming quarters.
2Q results showed that the mortality exposure for RGA remains manageable with the company still generating an operating profit despite elevated deaths related to COVID-19. Since that time, there are signs that mortality is improving with CDC data showing that U.S. deaths (from all causes) is now below its seasonal trend compared to prior years. The next couple of quarters should provide increasing comfort to investors that COVID-19 will definitively be an earnings event and not a capital event.
The pandemic has driven greater demand for life insurance policies with life insurance applications for the industry up +18.9% YoY in July and +9.1% in August. RGA stands to benefit should a secular growth trend emerge
show sort by |
Are you sure you want to close this position Reinsurance Group of America?
By closing position, I’m notifying VIC Members that at today’s market price, I no longer am recommending this position.
Are you sure you want to Flag this idea Reinsurance Group of America for removal?
Flagging an idea indicates that the idea does not meet the standards of the club and you believe it should be removed from the site. Once a threshold has been reached the idea will be removed.
You currently do not have message posting privilages, there are 1 way you can get the privilage.
Apply for or reactivate your full membership
You can apply for full membership by submitting an investment idea of your own. Or if you are in reactivation status, you need to reactivate your full membership.
What is wrong with message, "".